- $14.90m
- $10.63m
- 30
- 14
- 56
- 25
Annual balance sheet for Edesa Biotech, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.03 | 7.21 | 7.84 | 7.09 | 5.36 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.217 | 0.087 | 3.3 | 1.26 | 0.627 |
| Prepaid Expenses | |||||
| Total Current Assets | 5.64 | 8.1 | 12.1 | 9.09 | 6.44 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.073 | 0.175 | 0.112 | 0.031 | 0.1 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 5.72 | 10.8 | 14.6 | 11.6 | 8.89 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.462 | 1.53 | 1.46 | 2.14 | 1.82 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.462 | 1.65 | 1.53 | 2.18 | 1.84 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 5.26 | 9.11 | 13.1 | 9.39 | 7.05 |
| Total Liabilities & Shareholders' Equity | 5.72 | 10.8 | 14.6 | 11.6 | 8.89 |
| Total Common Shares Outstanding |